What does this research mean for the field?

Intravenous administration of the chimeric 7E3 antibody, in combination with heparin and aspirin, can rapidly initiate coronary reflow in acute myocardial infarction without the use of exogenous plasminogen activators. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the effectiveness of intravenous chimeric 7E3 antibody in restoring coronary flow during myocardial infarction without using thrombolytic agents.

April 1, 1997Circulation

Restoration of Coronary Flow in Myocardial Infarction by Intravenous Chimeric 7E3 Antibody Without Exogenous Plasminogen Activators

View Full Paper

Ask AI

Bookmark

Why the study?

Does intravenous chimeric 7E3 antibody improve coronary reflow in patients with acute myocardial infarction without exogenous plasminogen activators?

Population

14 dogs with left anterior descending coronary artery thrombosis produced by endothelial trauma and thrombin…

Comparison

Intravenous chimeric 7E3 antibody administered… vs In dogs: heparin alone, or heparin and aspirin…

Design

Case_series

Follow-up

10 minutes

Authors

HGHerman K. GoldInterventional Cardiology HGHarry D. GarabedianUniversity of Vermont RDRobert E. DinsmoreAmerican Heart Association

Discussion

Member takes

Implication

May aid reflow in AMI without thrombolytics; leaves open efficacy in randomized trials.

Key Points

To evaluate the effectiveness of intravenous chimeric 7E3 antibody in restoring coronary flow during myocardial infarction without using thrombolytic agents.
Produced coronary artery thrombosis in 14 dogs using endothelial trauma and thrombin; monitored reflow with flow probe during treatments with heparin, heparin plus aspirin, and heparin plus aspirin plus 7E3.
Administered intravenous c7E3 in 13 human patients before primary angioplasty, combined with heparin and aspirin.
Stable reflow observed in 80% of dogs treated with heparin, aspirin, and 7E3, achieving >25% of prestenotic flow in 50±9 minutes.
TIMI flow improved in 85% of patients 10 minutes post-c7E3, with average TIMI grade increasing from 0.31±0.5 to 1.54±0.8 (P<.001).
Thrombus length decreased to 5.1±3.5 mm after treatment with c7E3, with no reported complications.

Structured PICO

Does intravenous chimeric 7E3 antibody improve coronary reflow in patients with acute myocardial infarction without exogenous plasminogen activators?

Population

14 dogs with left anterior descending coronary artery thrombosis produced by endothelial trauma and thrombin instillation, and 13 patients with acute myocardial infarction and TIMI grade 0 or 1 flow.

Intervention

Intravenous chimeric 7E3 antibody (c7E3) administered 10 minutes before primary angioplasty, with pretreatment of heparin and oral aspirin.

Comparator

In dogs: heparin alone, or heparin and aspirin. In humans: none (before-and-after comparison).

Outcome

Coronary reflow (TIMI flow grade) at 10 minutes.surrogate

Intravenous chimeric 7E3 antibody combined with heparin and aspirin can initiate coronary reflow in acute myocardial infarction prior to angioplasty without exogenous thrombolytic agents.

Cite This Study

Gold et al. (1997) studied this question.

synapsesocial.com/papers/6a1bf08d4ebd09f3dfa93b53 https://doi.org/10.1161/01.cir.95.7.1755

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Restoration of Coronary Flow in Myocardial Infarction by Intravenous Chimeric 7E3 Antibody Without Exogenous Plasminogen Activators

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Restoration of Coronary Flow in Myocardial Infarction by Intravenous Chimeric 7E3 Antibody Without Exogenous Plasminogen Activators

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider